PS
CBAY

Principal Securities’s Cymabay Therapeutics CBAY Stock Holding History

Principal Securities’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12
Closed -$283 – 3405
2023
Q4 		$283 Buy
+12
New +$214 ﹤0.01% 3118

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Principal Securities's CBAY Position: Q1 2024 in Review

Principal Securities sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 12 shares — an estimated $283 sold.

Principal Securities first reported a position in CBAY in Q4 2023 and held it in 1 quarter. The position peaked at $283 in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Principal Securities reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Principal Securities sold 12 Cymabay Therapeutics shares in Q1 2024, an estimated $283.
  • Principal Securities first reported a position in Cymabay Therapeutics in Q4 2023 and held it in 1 quarter.
  • Principal Securities's Cymabay Therapeutics position peaked at $283 in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Principal Securities's 13F filing for Q1 2024, filed 10 May 2024.